Hot Life Science Investor Mandate 1: Mezzanine Debt Fund Looking to Invest Directly in Healthcare, Research Institutions

9 Aug
A mezzanine debt fund with offices across the US is currently focused on structured financings of commercialized biopharmaceutical products and medical technologies. The firm’s total AUM is approximately $400 Million. Collectively, the fund has completed more than 50 royalty transactions representing nearly $4 billion in capital over the past 15 years.

The fund is heavily invested in healthcare investing that focuses on IP investments in FDA-approved biopharmaceutical assets through royalty bonds, structured debt, revenue interests and traditional royalty monetization. Typically, they target investments between $20 and $200 million and work directly with leading healthcare companies and research institutions.

Typical financings are intended to healthcare organizations fund pipeline development, make acquisitions, and expand into new markets—all with an adaptable source of capital. The firm’s primary source of collateral is derived from commercialized products.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: